Pneumovax 23 Market 2026–2035 expanding pneumococcal vaccination

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Pneumovax 23 Market Across 2026–2030?

Historical expansion was driven by the broadening of national immunization protocols, an increasing occurrence of pneumococcal infections among older demographics, the widespread availability of polysaccharide vaccines, a surge in preventive healthcare programs, and heightened awareness regarding vaccination.

The anticipated growth during the forecast period is fueled by escalating investments in adult vaccination initiatives, a heightened emphasis on preventing infectious diseases, the expansion of immunization services offered by pharmacies, a growing demand for long-term vaccine-derived immunity, and advancements in vaccine storage and distribution. Concurrently, significant trends anticipated in the forecast period include a sharpened focus on immunization programs for adults and the elderly, an increasing need for pneumococcal disease prevention, the wider adoption of proactive vaccination strategies, the expansion of public health immunization campaigns, and improved cold-chain vaccine management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20333&type=smp

Which Market Drivers Are Supporting The Expansion Of The Pneumovax 23 Market?

The pneumovax 23 market is projected to expand due to the rising occurrence of pneumococcal diseases. These infections, caused by *Streptococcus pneumoniae* (pneumococcus), range from mild issues like sinusitis and otitis media to severe conditions such as pneumonia and meningitis, often requiring hospital care. The increased incidence is linked to reduced vaccination rates during the COVID-19 pandemic, elevated risks for those with chronic health issues, and a rise in respiratory infections after social restrictions were lifted. Pneumovax 23 offers protection against pneumococcal diseases by immunizing against 23 strains of *Streptococcus pneumoniae*, thereby lowering the risk of infections like pneumonia, meningitis, and bacteremia. As an illustration, in June 2025, the Office for Health Improvement and Disparities, a UK government body, reported that emergency hospital admissions for pneumonia in England climbed by 16% in the financial year ending 2024 compared to the previous year, reaching a rate of 430 per 100,000 people and totaling approximately 252,912 admissions. Consequently, the global increase in pneumococcal diseases is fueling the growth of the pneumovax 23 market. The growing rate of urbanization is anticipated to fuel the expansion of the pneumovax 23 market in the coming years. This increase in urbanization is driven by industrialization, which creates better employment prospects in cities, improved access to education and healthcare, and the general appeal of urban lifestyles that draw people from rural areas seeking a higher quality of life. Urban populations generally have enhanced access to health education and awareness efforts, which can lead to greater vaccination coverage as individuals recognize the importance of preventing pneumococcal diseases. For example, in April 2023, a World Bank Group report indicated that about 56% of the global population, or 4.4 billion people, reside in urban areas, a trend expected to persist with the urban population nearly doubling by 2050, reaching close to 70%. Furthermore, urban land consumption is outpacing population growth by up to 50%, with an estimated 1.2 million square kilometers of new urban area projected by 2030. Thus, the ascent of urbanization is propelling the growth of the pneumovax 23 market.

What Segmentation Levels Are Considered In The Pneumovax 23 Market?

The pneumovax 23 market covered in this report is segmented –

1) By Formulation: Pneumococcal Polysaccharide Vaccine (PPV), Pneumococcal Conjugate Vaccine (PCV)

2) By Clinical Indication: Pneumococcal Disease Prevention

3) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Pharmacies

Which Leading Firms Are Contributing To The Growth Of The Pneumovax 23 Market?

Major companies operating in the pneumovax 23 market are Merck & Co. Inc. (Merck Sharp & Dohme Corp.)

Read the full pneumovax 23 market report here:

https://www.thebusinessresearchcompany.com/report/pneumovax-23-global-market-report

How Is The Pneumovax 23 Market Distributed Across Key Geographic Regions?

North America was the largest region in the pneumovax 23 market in 2025. The regions covered in the pneumovax 23 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pneumovax 23 Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20333&type=smp

Browse Through More Reports Similar to the Global Pneumovax 23 Market 2026, By The Business Research Company

Commercial P2P Cdn Market Report 2026

https://www.thebusinessresearchcompany.com/report/commercial-p2p-cdn-global-market-report

Polybutylene Terephthalate Pbt Market Report 2026

https://www.thebusinessresearchcompany.com/report/polybutylene-terephthalate-pbt-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795